Furthermore, pharmacological inhibition of OS via the NOX inhibitor apocynin (Apo) downregulates AR expression, thereby ameliorating BPH through the AR/TGF-β/NOX4 signaling axis. The gene discussed is TGFB1; the disease is benign prostatic hyperplasia.